Endocannabinoid System Biomarkers in Alzheimer’s Disease.

por jcdadm.website | nov 17, 2022 | Publication

Ferreira PCL, Bellaver B, Povala G, Brum WS, Tissot C, Badji A, Sloan ME, Benedet AL, Rosa-Neto P, Ashton NJ, Pascoal TA, Leuzy A, Zimmer ER. Cannabis Cannabinoid Res. 2022 Nov 17. doi: 10.1089/can.2022.0151. Online ahead of print.

The association of age-related and off-target retention with longitudinal quantification of [18F]MK6240 tau-PET in target regions.

por jcdadm.website | nov 17, 2022 | Publication

Tissot C, Servaes S, Lussier FZ, Ferrari-Souza JP, Therriault J, Ferreira PCL, Bezgin G, Bellaver B, Teixeira Leffa D, Mathotaarachchi SS, Chamoun M, Stevenson J, Rahmouni N, Kang MS, Pallen V, Poltronetti NM, Wang YT, Fernandez-Arias J, Benedet AL, Zimmer ER, Soucy...

Subjective cognitive decline in Brazil: Prevalence and association with dementia modifiable risk factors in a population-based study.

por jcdadm.website | nov 14, 2022 | Publication

Borelli WV, Zimmer ER, Bieger A, Coelho B, Pascoal TA, Chaves MLF, Amariglio R, Castilhos RM. Alzheimers Dement (Amst). 2022 Nov 14;14(1):e12368. doi: 10.1002/dad2.12368. eCollection 2022.

Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease.

por jcdadm.website | out 3, 2022 | Publication

Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, Lussier FZ, Schroeder FA, DuBois JM, Hightower BG, Gilbert TM, Zürcher NR, Wang C, Hopewell R, Chakravarty M, Savard M, Thomas E, Mohaddes S, Farzin S, Salaciak...

Staging of Alzheimer’s disease: past, present, and future perspectives.

por jcdadm.website | set 1, 2022 | Publication

Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P. Trends Mol Med. 2022 Sep;28(9):726-741. doi: 10.1016/j.molmed.2022.05.008. Epub 2022 Jun 15.